Supplementary Materials




Figure S1. Flow diagram of patient enrollment.




Figure S2. PPV of severe COVID-19 against medical chart review by month. A total of 300 patients who met the Pfizer/BioNTech COVID-19 vaccine trial definition of severe COVID-19 illness was selected by random sampling without replacement. Data for November were available only up to November 19, 2020.

Table S1. COVID-19 diagnostic measures

Diagnostic measure	Overall (March–November [†] 2020) N = 354,124		
PCR			
Patients with ≥1 PCR test, n (%)	335,043 (94.6)		
Patients with ≥1 positive test	21,775 (6.5)		
Patients without any positive tests	313,268 (93.5)		
Patients with ≥1 negative test	323,031 (96.4)		
Number of PCR tests per patient, mean \pm SD [median]	$2.2 \pm 1.7 [2.0]$		
Total number of PCR tests	726,652		
Positive, n (%)	42,930 (5.9)		
Negative, n (%)	683,722 (94.1)		
ICD-10-CM diagnosis code (U07.1)¶			
Patients with ≥1 ICD-10-CM diagnosis code (U07.1), n (%)	39,576 (11.2)		
Number of ICD-10-CM codes per patient, mean ± SD [median]	3.0 ± 5.4 [2.0]		

Data are shown as n (%) unless otherwise indicated.

Abbreviations: COVID-19, coronavirus disease 2019; ICD-10-CM, International Classification of Diseases 10th Revision, Clinical Modification; PCR, polymerase chain reaction; SD, standard deviation.

[†]Data for November were available only up to November 19, 2020.

Defined as "COVID-19, virus identified", effective April 1, 2020.

Table S2. Frequency of severe or critical COVID-19 illness endpoints per WHO definition in patients hospitalized with COVID-19

Endpoint	All patients hospitalized with COVID-19 N = 3,580	
Patients meeting WHO definition of severe or critical COVID-19 illness, n (%)	2,822 (78.8)	
Patients meeting WHO definition of severe COVID-19 illness [†] , n (%)	2,697 (75.3)	
$\mathrm{SpO}_2{}^{\ddagger}$		
Patients with SpO ₂ available	3,578 (99.9)	
$SpO_2 < 90\%$	1,931 (54.0)	
Respiratory frequency [‡]		
Patients with respiratory frequency available	3,573 (99.8)	
Respiratory frequency >30 breaths/min	1,626 (45.5)	
Signs of severe respiratory distress [¶]	1,705 (47.6)	
Patients meeting WHO definition of critical COVID-19 illness§, n (%)	1,454 (40.6)	
Requiring life-sustaining treatment	994 (27.8)	
Vasopressors ¹	914 (25.5)	
Invasive ventilation [#]	738 (20.6)	
Noninvasive ventilation [#]	605 (16.9)	
Acute respiratory distress syndrome¶	1,167 (32.6)	
Sepsis [¶]	494 (13.8)	
Septic shock ¶	334 (9.3)	

[†]Patients meeting the WHO definition of severe COVID-19 illness had at least one of the listed endpoints during hospitalization with COVID-19.

[‡]If a patient had multiple measurements on the same day, the most severe result was used.

[¶]Identified using diagnosis codes.

[§]Patients meeting the WHO definition of critical COVID-19 illness had at least one of the listed endpoints during hospitalization with COVID-19.

^IIdentified through string searches of medication names including dopamine, dobutamine, milrinone, levosimendan, epinephrine, norepinephrine, vasopressin, and phenylephrine.

^{*}Identified from structured procedure data based on procedure codes and from respiratory therapy-related procedure data curated by Mass General Brigham. Abbreviations: COVID-19, coronavirus disease 2019; SpO₂, oxygen saturation; WHO, World Health Organization.

Table S3. Validation of severe or critical COVID-19 illness endpoints per WHO definition against medical chart review

En du cin4	PPV ^{†‡}		
Endpoint	TP	TP + FP	PPV % (95% CI)¶
Patients meeting WHO definition of severe or critical COVID-19 illness	190	244	77.9 (72.1, 82.9)
Patients meeting WHO definition of severe COVID-19 illness§	186	237	78.5 (72.7, 83.5)
$SpO_2 < 90\%$	157	172	91.3 (86.0, 95.0)
Respiratory frequency >30 breaths/min	127	136	93.4 (87.8, 96.9)
Signs of severe respiratory distress [#]	111	149	74.5 (66.7, 81.3)
Patients meeting WHO definition of critical COVID-19 illness ^{††}	108	119	90.8 (84.1, 95.3)
Requiring life-sustaining treatment	79	85	92.9 (85.3, 97.4)
Vasopressors ^{‡‡}	76	81	93.8 (86.2, 98.0)
Invasive ventilation¶	64	66	97.0 (89.5, 99.6)
Noninvasive ventilation ¶	48	49	98.0 (89.1, 99.9)
Acute respiratory distress syndrome [#]	95	102	93.1 (86.4, 97.2)
Sepsis [#]	51	52	98.1 (89.7, 100.0)
Septic shock [#]	37	38	97.4 (86.2, 99.9)

[†]Validation was conducted in a subset of the 300 patients who met the WHO definition of severe or critical COVID-19 illness based on codified data.

[‡]PPV was calculated as TP/ (TP + FP), where TP and FP were patients meeting the WHO definition of severe COVID-19 illness by medical chart review and those with the corresponding endpoint determined from codified data, respectively.

Exact CIs are presented for each validation measure.

[§]Patients who met the WHO definition of severe COVID-19 illness had at least one of the listed endpoints during hospitalization with COVID-19.

¹Endpoints were identified from clinical sign-related or laboratory data curated by Mass General Brigham.

^{*}Identified from structured diagnosis data based on diagnosis codes.

^{††}Patients who met the WHO definition of critical COVID-19 illness had at least one of the listed endpoints during hospitalization with COVID-19.

^{‡‡}Identified through string searches of medication names including dopamine, epinephrine, norepinephrine, and vasopressin.

^{**}Identified from structured procedure data based on procedure codes and from respiratory therapy-related procedure data curated by Mass General Brigham.

Abbreviations: CI, confidence interval; COVID-19, coronavirus disease 2019; FP, false positive; PPV, positive predictive value; SpO₂, oxygen saturation; TP, true positive; WHO, World Health Organization.

Table S4. Validation of non-severe COVID-19 illness in codified data against medical chart review

Endnaint		NPV ^{†‡}		
Endpoint	TN	TN + FN	NPV % (95% CI)¶	
Patients not meeting vaccine trial definition of severe COVID-19 illness§	75	100	75.0 (65.3, 83.1)	
Patients not meeting WHO definition of severe or critical COVID-19 illness	66	72	91.7 (82.7, 96.9)	

[†]NPV was calculated based on a subgroup of 100 patients who did not meet the Pfizer/BioNTech COVID-19 vaccine trial definition of severe COVID-19 illness based on codified data.

Abbreviations: CI, confidence interval; COVID-19, coronavirus disease 2019; FN, false negative; NPV, negative predictive value; TN, true negative; WHO, World Health Organization.

[‡]NPV was calculated as TN/ (TN + FN), where TN and FN were patients who did not meet the definition of severe COVID-19 illness based on chart review and codified data, respectively.

[¶]Exact CIs are presented for each validation measure.

[§]Patients with hospitalizations that were determined to not be COVID-19–related through chart review were categorized as TN.